Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease

Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference

EISAI PRESENTS LATEST CLINICAL FINDINGS SUGGESTING INHIBITION OF TAU PROPAGATION BY ANTI-MTBR TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD)